SOLICITATION NOTICE
H -- Vaccine Analytic Unit (VAU)Serum Anti-ganglioside Antibodies
- Notice Date
- 8/3/2010
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2010-N-12694
- Archive Date
- 9/8/2010
- Point of Contact
- Berta L Biltz, Phone: 770-488-2643
- E-Mail Address
-
boh9@cdc.gov
(boh9@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- The Centers for Disease Control and Prevention, Division of Healthcare Quality Promotion (DHQP), Immunization Safety Office's (ISO) is seeking to award a Time and Materials contract under FAR Part 12 to have the Medical College of Georgia test and deliver serum assays to determine anti-ganglioside antibodies with GM1, GT1a, GD1a, and GQ1b specificity and titers will be performed on an estimated 2,000 serum specimens. In recent years, mounting evidence implicates the involvement of anti-glycosphingolipid (GSL) antibodies in the pathogenesis of peripheral neuropathies such as Guillain-Barré syndrome (GBS). Potential antigens include gangliosides, sulfated GSLs, and neutral GSLs. These GSLs are most abundant in nervous tissues and represent targets of circulating antibodies and immune cells in patients with these neurological disorders. Since there is growing awareness that anti-GSL antibodies arise as the result of antecedent infection, it has been generally accepted that these antibodies arise from a variety of glycoconjugate antigens through a molecular mimicry mechanism. These glycoconjugates include various bacterial lipooligosaccharides (LOSs) and viral hemagglutinins. In light of the involvement of public health to these antigens as a result of vaccination (e.g., swine flu and H1N1), it would be crucial to examine the nature of the serum anti-GSL antibodies and evaluate their putative involvement in GBS. The most common detecting procedures are enzyme-linked immunosorbent assay (ELISA) and thin-layer chromatography-immunooverlay assay. These procedures are highly sensitive and specific, but require a supply of purified and authentic glycoconjugate antigens. It also requires considerable expertise to interpret the results and to differentiate the positives from false positives. Additionally, the use of these procedures requires comparison of patient sera with normal and pathological controls. For these reasons, very few laboratories in the US can undertake this task. MCG Laboratory has been actively engaged in the development of these methods for the last 20 years. Based on the above, we believe that no other source, but the Medical College of Georgia (MCG) Laboratory is uniquely qualified to perform this requirement. The anticipated period of performance shall be 24 months from date of award. However, all responsible sources responding to this announcement will be considered. All questions/concerns/expression of interest about this announcement shall ONLY be submitted via e-mail to BBiltz@cdc.gov. The anticipated solicitation issue date is 08/10/2010. It is your responsibility to keep up with additional postings regarding this anouncement on the Fedbizopps Website.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2010-N-12694/listing.html)
- Place of Performance
- Address: Augusta, Georgia, 30912-4810, United States
- Zip Code: 30912-4810
- Zip Code: 30912-4810
- Record
- SN02226599-W 20100805/100803235108-504307993acb61066b0b4a3a78ab33a2 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |